Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CSIRO based drug effective against bird flu

20.02.2004



Drugs based on CSIRO’s research into the influenza virus have been shown to be effective, in laboratory tests, against a sample of an H5N1 influenza virus currently infecting chickens in Asia.

CSIRO Health Sciences and Nutrition scientist, Dr Jenny McKimm-Breschkin, has tested the ability of the flu drug Relenza™ to inhibit the virus, known as H5N1 strain, which has killed millions of chickens in Asia and has been responsible for several human deaths this year.

The tests, used to monitor virus sensitivity to drugs, have shown that the drug Relenza™ is as effective, in laboratory experiments, against this bird flu as it is against other strains of flu that affect humans.



"There is a direct correlation between enzyme sensitivity as measured by these laboratory tests and the ability of the drug to prevent the virus from multiplying," said Dr McKimm-Breschkin.

In 1999, the world’s first drug effective against all strains of influenza was released onto the world market. Relenza™ was designed based on CSIRO’s discovery that there was a small section on the surface of the influenza virus that doesn’t change between strains of flu. Designing a drug to inhibit the action of this part of the virus meant it would be very difficult for the virus to mutate to avoid binding the drug. No drug resistance has been seen globally in any previously healthy patient treated with Relenza™.

Subsequently a second drug, Tamiflu™, was developed based on CSIRO research. Its manufacturers claim that pre-clinical trials provide reassurance that it could be effective against bird flu.

The Asian bird flu has not been shown to be passed from human to human. All those who have died from this disease have caught it directly from infected birds. The current strategy for preventing this virus from spreading further and endangering more humans has been to cull millions of chickens in Asian farms and markets.

"In the event that the disease does mutate into a form which can be passed from human to human it is important to know that we already have a treatment available," said Dr McKimm-Breschkin. "The fact that our experiments show that in the laboratory this Australian designed drug is effective against bird flu again shows just how important a discovery this was."

In order to establish that Relenza™ is effective in humans infected with bird flu, clinical data from humans will be needed.

The same techniques used in the development of Relenza™ are being employed by CSIRO to fight other diseases such as cancer, psoriasis and inflammatory diseases like rheumatoid arthritis.

It should be noted that CSIRO receives a royalty income from sales of Relenza™. The assay results reported here have been conducted independently of the manufacturers of Relenza™.

More information:

Mr Warrick Glynn, CSIRO Health Sciences and Nutrition,
PH: 61 3 9662 7344, Mobile: 0408 117 846
Email: Warrick.Glynn@csiro.au

Rosie Schmedding | CSIRO
Further information:
http://www.csiro.au/index.asp?type=mediaRelease&id=PrBirdFlu5

More articles from Agricultural and Forestry Science:

nachricht How much drought can a forest take?
20.01.2017 | University of California - Davis

nachricht Plasma-zapping process could yield trans fat-free soybean oil product
02.12.2016 | Purdue University

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>